Aperion Biologics

Aperion Biologics is a clinical-stage medical device company developing a technique to make animal-tissues usable for human applications.

Aperion Biologics, Inc. is a clinical-stage medical device company addressing the need for alternatives to human-based grafts with animal-based tissue technology. Aperion Biologics, Inc. developed and patented a technique to make animal-tissues usable for human applications without causing rejection. The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both “humanizes” and sterilizes the tissues without affecting their biomechanical or biological properties. This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled. Aperion’s Z-Process of humanizing and sterilizing tissue can be applicable to a variety of tissues from orthopedic ligaments, bone, and meniscus to valves and vessels to soft tissue grafts for augmentation and repair. The company’s lead product for knee ligament reconstruction, the Z-Lig ACLR Device, is currently under clinical investigation and not commercially approved for sale in the United States, European Union or other markets.